Stocks and Investing
Stocks and Investing
Tue, November 2, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, November 1, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yatin Suneja Upgraded (ACAD) to Strong Buy and Held Target at $23 on, Nov 1st, 2021
Yatin Suneja of Guggenheim, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Held Target at $23 on, Nov 1st, 2021.
Yatin has made no other calls on ACAD in the last 4 months.
There are 4 other peers that have a rating on ACAD. Out of the 4 peers that are also analyzing ACAD, 2 agree with Yatin's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Downgraded from Buy to Hold and Held Target at $20 on, Thursday, October 14th, 2021
- Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $25 on, Thursday, August 5th, 2021
These are the ratings of the 2 analyists that currently disagree with Yatin
- Joseph Stringer of "Needham" Maintained at Strong Buy with Decreased Target to $26 on, Thursday, August 5th, 2021
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $28 on, Thursday, August 5th, 2021
Contributing Sources